Daniel DeSalvo, MD
- Diabetes and Endocrinology
Director of Strategic Collaboration, Texas Children’s Diabetes & Endocrine Care Center
Type 1 Diabetes Clinic
Associate Professor, Baylor College of Medicine
Languages: English
Get to know Daniel DeSalvo, MD
Personal Statement
I joined the TCH Section of Pediatric Diabetes and Endocrinology in July 2015 after completing a postdoctoral fellowship at Stanford University. I serve as the Type 1 Diabetes Clinic Lead and Director of Strategic Collaboration for the Texas Children’s Diabetes & Endocrine Care Center. My overarching career goal as a pediatric endocrinologist is to provide compassionate and comprehensive care to youth with diabetes, and to advance clinical care through patient-centered research and quality improvement endeavors. My clinical and research focus is on emerging diabetes technology and therapies (including continuous glucose monitoring and closed-loop automated insulin delivery systems) for improving clinical outcomes and reducing the burden of care. It was through my personal experience living with type 1 diabetes, and a desire to help others on a similar journey that motivated me to become a pediatric endocrinologist.
Education
Organizations
* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.
Reviews
Publications
DeSalvo DJ, Bode B, Forlenza GP, Laffel LM, Buckingham BA, Criego A, Schoelwer M, MacLeish SA, Sherr JL, Hansen D, Ly TT. Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod 5 Automated Insulin Delivery System. Diabetes Technology & Therapeutics. 2024 Feb. PMID: 38277156
Crain ER, Ramphul R, Butler AM, Huang X, Minard CG, Redondo MJ, DeSalvo DJ. Social determinants of health impact on diabetes device use and clinical outcomes in youth with type 1 diabetes. Pediatric Diabetes. 2023 Oct
DeSalvo DJ, Noor N, Xie C, Corathers S, Majidi S, McDonough RJ, Polsky S, Izquierdo R, Rioles N, Weinstock R, Obrynba K, Roberts A, Vendrame F, Sanchez F, Ebekozien O. Patient demographics and clinical outcomes among type 1 diabetes patients using continuous glucose monitors: Data from T1D Exchange real-world observational study. Journal of Diabetes Science and Technology. 2023 Mar; 17(2):322-328. PMID: 34632823
DeSalvo DJ, Lanzinger S, Noor N, Steigleder-Schweiger C, Ebekozien O, von Sengbusch K, Jones NHY, Laubner K, Maahs DM, Holl R. Transatlantic Comparison of Pediatric Continuous Glucose Monitoring use in the DPV Initiative and T1D Exchange Quality Improvement Collaborative. Diabetes Technology & Therapeutics. 2022 Dec; 24(12):920-924. PMID: 35947079
Dave D, DeSalvo DJ, Haridas B, McKay S, Shenoy A, Koh CJ, Lawley M, Erraguntla M. Feature-based machine learning model for real-time hypoglycemia prediction. Journal of Diabetes Science and Technology. 2021 Jul; 15(4):842-855. PMID: 32476492
Laffel LM, Kanapka LG, Beck RW, Bergamo K, Clements MA, Criego A, DeSalvo DJ, Goland RS, Hood K, Liljenquist D, Messer LH, Monzavi R, Mouse TJ, Prahalad P, Sherr J, Simmons JH, Wadwa RP, Weinstock RS, Willi SM, Miller KM. Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes. JAMA. 2020 Jun 16;323(23):2388-2396. PMID: 32543683
